Introduction
Anticoagulation is effective in reducing ischaemic events in acute coronary syndromes (ACS). 1 Fondaparinux (ArixtraV R ) is a synthetic
Factor Xa inhibitor that is structurally similar to the anti-thrombin binding site of heparin. It acts by selectively binding to antithrombin III to potentiate the innate neutralization of Factor Xa by antithrombin III. It is approved in the USA and Europe for the prevention and treatment of venous thromboembolic events. 2, 3 Fondaparinux has been studied in three clinical trials in patients with ACS, [4] [5] [6] and in 2007 it was approved in the European Union and Canada for the treatment of unstable angina/non-ST-segment elevation myocardial infarction (UA/NSTEMI) and for the treatment of ST-segment elevation myocardial infarction (STEMI) in patients who are managed with fibrinolytics or who initially received no other form of reperfusion therapy. 3 Additionally, the prescribing information for fondaparinux 3 and international treatment guidelines for management of ACS 1,7-10 recommend the use of adjunctive anticoagulation (such as unfractionated heparin [UFH] ) in patients treated with fondaparinux undergoing percutaneous coronary intervention (PCI). Physician adherence to prescribing information and treatment guidelines varies and is important for patient outcomes. [11] [12] [13] The purpose of this post-approval study was to assess whether fondaparinux is being used as recommended, by evaluating physician adherence to the prescribing information for the administration of adjunctive anticoagulation during PCI in patients with ACS treated with fondaparinux.
Methods

Selection of study sites and patients
This retrospective hospital-based chart-review study was conducted in Canada, France, Germany, Greece, Poland, and Sweden from 2008 to 2010. Participating hospitals had fondaparinux on formulary for ACS and the ability to perform PCI. To ensure representativeness within each country, a minimum of five sites per country were targeted for inclusion.
To be eligible for inclusion in this study, patient records must have included evidence of the following criteria: (i) hospital admission with a final diagnosis of UA/NSTEMI or STEMI, (ii) PCI during hospitalization, (iii) received treatment with fondaparinux during hospitalization, and (iv) no concurrent enrolment in any clinical studies that could influence the in-hospital use of anticoagulation.
Review and approval of the study protocol by Ethics Committees (ECs) or Institutional Review Boards (IRBs) was obtained at each study site. Due to the observational nature of the study and the data collected, requirement of individual patient informed consent was not expected, and waivers of patient informed consent were approved by an EC/IRB in all countries.
Study objectives and endpoints
The primary endpoint was the proportion of patients treated with fondaparinux who received an adjunctive anticoagulant during PCI. Adherence to the prescribing information was considered satisfied if any anticoagulant (including UFH, enoxaparin, bivalirudin, or other parenteral anticoagulant agent) was administered during the PCI. Secondary endpoints included the proportion of patients with UA/NSTEMI or STEMI administered a parenteral anticoagulant during PCI, the proportion of patients administered UFH during PCI, and the proportion of patients given an 'other' specified anticoagulant during PCI.
Additionally, a post hoc analysis was conducted to explore the timing of fondaparinux administration prior to and after primary PCI in the sub-set of STEMI patients undergoing the procedure. A primary PCI was defined as one conducted in STEMI patients within 12 h of presentation/diagnosis in the absence of prior administration of thrombolytics. Rescue PCI postthrombolysis, facilitated PCI, and elective PCI were considered nonprimary PCI.
Data collection
Medical record abstractors at each site obtained information regarding the use of fondaparinux, the use of adjunctive anticoagulants, and the details of the PCI procedure from patient records. The following patient information was extracted during a single medical record review: gender, age at hospital admission, date/time of admission and discharge, ACS presentation, ACS discharge diagnosis, date and time of in-hospital fondaparinux use up to eight doses (dose level, route of administration, and administration date and time), and PCI (type, date, start/stop time, and use of adjunctive anticoagulant). Specific reasons for not administering any adjunctive anticoagulant or an anticoagulant other than UFH at the time of PCI (e.g. an active/recent bleeding event, elevated bleeding risk, history of thrombosis, standard practice to use other anticoagulant, other medical decision to deviate, or reason not identified) were documented.
Sample size and power calculations
This study was powered to ensure that the estimated 95% confidence interval (CI) for the adherence rate would have a lower bound greater than 60%, given the assumed adherence rate of 80% and an intraclass correlation (ICC) of 0.25 with 90% power. All sample size calculations assumed clustered binary data, where the cluster was defined as the physician practice 14 and were based on the Donner and Klar 15 estimator of the adherence rate. The degree of correlation within a cluster was quantified by the ICC. This approximated the sample size needed in the repeated measures modelling context that was used in the generalized estimating equations (GEEs). While the study was originally powered to assess physician adherence in both STEMI and UA/NSTEMI sub-groups, fewer than expected STEMI patients were included, resulting in insufficient power to reliably measure physician adherence among STEMI patients.
Statistical methods
Descriptive statistics were used to summarize patient demographics and the in-hospital use of fondaparinux. Adjunctive anticoagulant adherence was estimated using GEEs, which use a logit link and are an extension of standard logistic regression modelling to the clustered binary outcome setting. Physician practice defined the clusters, and the working correlation matrix was assumed to be compound symmetric. In situations where the correlation coefficient was negative, the correlation matrix was changed from compound symmetry to independent structure, and revised adjusted CIs were calculated using methods described by Hanley et al. 16 Physician adherence was estimated using GENMOD Procedure, and the reasons for non-adherence were summarized.
Results
Data concerning 1056 patients were retrospectively collected from 27 sites in 6 countries. The study sites included large and small hospitals, as well as academic medical centres, ranging in size from 150 to Adjunctive use of anticoagulants at the time of percutaneous coronary intervention 2400 beds with 14-90 cardiology beds. Table 2 summarizes the in-hospital use of fondaparinux. Of the 1056 patients treated with fondaparinux and undergoing PCI, approximately 73% of patients received more than one fondaparinux dose by subcutaneous (SC) injection, with a median (range) of 3 (1-8) doses administered per patient. Administration of the first dose of fondaparinux by the intravenous (IV) route was extremely low (0.5% of patients), and no patient received more than one IV dose. Almost all doses (98.5%) were administered at the recommended 2.5 mg. A total of 18 doses in eight patients were administered at the 1.5 mg dose level, all of which were administered to patients with UA/ NSTEMI who had documented renal impairment. A total of 31 doses in 8 patients were administered at other dose levels. Three patients were administered one or more doses at 7.5 mg, one patient received a 5 mg dose, and one patient received both a 7.5 mg and a 5 mg dose. Three patients received one or more doses at 1.25 mg (assumed to be a data entry error, as no such dosage form exists). Across the participating countries, there were some differences in the number of fondaparinux doses administered; Germany and Greece had a median of four and five doses, respectively, while all other countries had a median of two doses.
Of the 1056 patients included in the study, 5 patients (4 with UA/ NSTEMI and 1 with STEMI at admission) underwent 2 PCIs; for the purposes of analysis, only the first PCI in these 5 patients was considered. Approximately 85% of all first PCIs conducted in the population were non-primary, and 70.4% of patients with an admission diagnosis of STEMI underwent primary PCI ( Table 3) . In the overall patient population, 59.0% and 7.6% of patients received their last dose of fondaparinux less than 24 h before, or more than 48 h before PCI, respectively. The remaining 19.3% of patients received their first dose of fondaparinux after PCI. Administration of an adjunctive anticoagulant other than fondaparinux during PCI occurred in 97.5% of patients (Table 4) , giving an adjusted adherence rate of 98.8% (95%CI 0.97-0.99). Approximately 86% of patients received UFH during PCI; bivalirudin, the second most commonly used agent, was administered to 107 (10.1%) patients. Eleven (1.0%) patients received other parenteral anticoagulant agents (enoxaparin or other direct thrombin inhibitors) and 26 (2.5%) patients received no adjunctive anticoagulant. Usage of an additional anticoagulant during PCI was broadly similar across UA/NSTEMI and STEMI patients. Across the participating countries, the use of additional anticoagulant during PCI was similar to that seen in the overall population, and the rates of usage were also consistently high (data not shown). In the five patients who underwent a second PCI, all but one procedure was performed with adjunctive UFH; one patient with STEMI at admission had a nonprimary PCI performed without an additional anticoagulant being administered.
Among the patients receiving UFH as the adjunctive anticoagulant during PCI, the majority (81.4%) received a fixed bolus dose of (median [range]) 5000 IU (1000-15 000 IU), while 7.2% of patients received a weight-adjusted dose of 87.5 IU/kg (50-200 IU/kg). No dose information was available for 11.3% of patients.
Of the 26 patients undergoing PCI without an additional anticoagulant, 3 received IV fondaparinux, 14 received IV glycoprotein IIb/IIIa inhibitors (abciximab or eptifibatide), and 9 received neither adjunctive parenteral anticoagulant nor antiplatelet therapy. The reasons for non-adherence were as follows: 13 patients received UFH in the emergency room or at the referring hospital (of which 12 were STEMI patients who underwent PCI soon after admission); 3 patients received IV fondaparinux during PCI; for 7 'standard practice to use adjunctive anticoagulant other than UFH during PCI' was noted, but no adjunctive anticoagulant was documented; for 1 patient, it was noted that there was 'no need as patient received 2 doses of fondaparinux'; and for 2 patients the 'reason could not be identified '. Finally, of the 159 patients with STEMI undergoing primary PCI, 70.4% were considered adherent with the recommendation not to administer fondaparinux less than 24 h prior to or during primary PCI. The remaining 47 (29.6%) patients undergoing primary PCI received fondaparinux less than 24 h prior to the procedure. Eleven patients had 'other coronary diagnosis' at admission (see Table 1 for details); at discharge 10 had a diagnosis of UA/NSTEMI and 1 had a diagnosis of STEMI. IV, intravenous; PCI, percutaneous coronary intervention; SC, subcutaneous; STEMI, ST-segment elevation myocardial infarction; UA/NSTEMI, unstable angina/non-ST-segment elevation myocardial infarction. Eleven patients had 'other coronary diagnosis'at admission (see Table 1 for details); at discharge 10 had a diagnosis of UA/NSTEMI and 1 had a diagnosis of STEMI. b One STEMI patient reported as having 'other anticoagulant' received abciximab/UFH. PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction; UA/NSTEMI, unstable angina/non-ST-segment elevation myocardial infarction; UFH, unfractionated heparin.
Discussion
Physicians' understanding of and adherence to prescribing information is essential for the safe and effective use of medications in patients. Despite this, there are few studies assessing physician adherence to prescribing information. In the case of fondaparinux, the recommendation to use adjunctive UFH when conducting PCI in ACS patients arose as a consequence of a sub-group analysis of OASIS-5 in UA/NSTEMI patients, which concluded that the addition of UFH during PCI reduced the risk of catheter thrombosis without increasing bleeding. 17 This observation was subsequently confirmed in the FUTURA/OASIS-8 study. 6 Treatment guidelines incorporating expert opinion expanded the recommendation to include agents that have anti-IIa activity, such as bivalirudin. 9, 10 Given that the switching of anticoagulant agents during the conduct of PCI is not usual clinical practice and the recommendation to do so is fondaparinux-specific, we considered it important to assess adherence in clinical practice. In our study, the high adherence to the use of an adjunctive anticoagulant during PCI in fondaparinux-treated patients indicates that physicians are following prescribing information and recommendations in international treatment guidelines. The majority of patients received UFH during PCI, and among those not receiving UFH, most received an alternative adjunctive anticoagulant, usually bivalirudin. These findings were consistent in each of the six participating countries and in both UA/NSTEMI and STEMI patients. Failure to administer adjunctive anticoagulation during PCI (i.e. non-adherence) was observed in only 2.5% of patients. However, approximately half of these patients received UFH in the emergency room or referring hospital shortly before the procedure.
The fondaparinux prescribing information also recommends that for patients undergoing PCI, UFH should be administered according to standard practice. 3 In our study, UFH as an adjunct to PCI was more likely to be given as a fixed bolus (median 5000 IU) rather than a weight-adjusted bolus (median 87.5 IU/kg). Treatment-guideline 1,9,10 recommendation for the use of standard-dose UFH (85 IU/ kg or 60 IU/kg if given with glycoprotein IIb/IIIa inhibition) are based on the FUTURA/OASIS-8 study, 6 which was conducted during a similar timeframe as our study. Physicians' adherence with recommendations for fondaparinux use in STEMI patients undergoing primary PCI (i.e. no administration immediately prior to or during PCI) was approximately 70%. However, this may be an underestimate since complete adherence would result in fondaparinux not being administered to these patients, thereby excluding them from the study. While the overall number of ACS patients undergoing PCI at the participating centres was not collected, the small number of STEMI patients included in this study suggests that the majority undergoing primary PCI are not treated with fondaparinux.
Although the study objectives did not include assessing physician adherence to the recommended dose, administration route, or duration of fondaparinux treatment, we found that the majority of patients received the recommended dose of fondaparinux (2.5 mg) 3 with only 0.5% of patients receiving a higher dose. The vast majority of patients were administered fondaparinux by the SC route, with limited use of IV administration, which is recommended for the initial dose in patients with STEMI. 3 The low use of IV administration in STEMI patients in our study may be a consequence of several factors, including the tendency to initiate fondaparinux post-PCI, particularly post-primary PCI. This was an unexpected finding in our study, since this strategy has not been studied and is not included in prescribing information or treatment guidelines. We have no data to explore the reasons or clinical outcomes of this practice; it may be a consequence of physicians' adaptation of the prescribing information to meet the clinical needs of patients in their care, or to simplify management with fondaparinux as patients urgently transfer through the catheterization laboratory. From the perspective of assessing physicians' adherence, which was defined as not administering fondaparinux immediately prior to or during primary PCI, we considered this post-PCI use as adherence provided that an adjunctive anticoagulant was administered.
The observed number of daily doses of fondaparinux administered (median 3) was lower than expected based on the recommended use for up to 8 days or until discharge, if earlier. 3 This recommendation is based on the OASIS-5 and OASIS-6 studies in UA/NSTEMI and STEMI patients, respectively. 4, 5 Both studies were completed in 2006 and reported overall treatment durations of 5 days, 4 and 7 or 8 days, depending on the reperfusion strategy used. 5 However, in the subset of UA/NSTEMI patients undergoing PCI 17 and the subsequent FUTURA/OASIS-8 study in UA/NSTEMI patients undergoing PCI, 6 the median fondaparinux treatment duration was 2.5 days and 3 days, respectively, with a median duration post-PCI of 2 days. 6 Thus, the fondaparinux treatment duration in these 2 studies in UA/NSTEMI patients undergoing PCI is consistent with our observations in clinical practice. Another factor that might influence total treatment duration, length of hospitalization was similar in our study and FUTURA/ OASIS-8 (medians 5 versus 4 days, respectively); length of stay was not reported in the two earlier studies. There were several limitations in our study. It was designed to assess physician understanding of the prescribing information by capturing adherence to the recommendation to administer an adjunctive anticoagulant during PCI to patients treated with fondaparinux. Patients were selected based on use of fondaparinux and were not all-comers regardless of treatment; consequently, our study is only informative on adherence with respect to one treatment used in the management of ACS.
We did not assess clinical outcomes associated with adherence or the consequences of non-adherence. Relationships between treatment and outcomes in an observational study of patients receiving multiple medications are difficult to demonstrate, as shown in two studies that investigated adherence to prescribing or treatment guidelines in patients with heart failure 12 or acute myocardial infarction. 13 In a large Swedish registry of over 40 000 NSTEMI patients, real-world use of fondaparinux was associated with a lower odds of major bleeding events and death relative to low-molecular weight heparin, with similar results in the sub-group of patients undergoing PCI; 18 however, whether these observations were as a consequence of adherence to treatment guidelines or prescribing information was not assessed. Recruitment in our study was slower than anticipated. Due to the small number of patients with STEMI included, the study was underpowered to reliably assess adherence among this sub-group. To achieve within-country representative sample, data from 168 patients in at least 5 sites per country were targeted. However, we did not meet our full target in 2 countries, and the data were obtained from only 3 sites in these 2 countries. Thus, the representativeness of the findings is uncertain. While every attempt was made to identify a representative sample of hospitals, those that did participate in the study may not truly reflect standard practice throughout a given country. Additionally, the six countries may not be representative of all countries where fondaparinux is administered to patients with ACS.
Finally, the criteria for patient eligibility included having a discharge diagnosis of ACS, receiving fondaparinux during admission, and undergoing a PCI. Following data collection, we observed that for some patients fondaparinux was only initiated post-PCI, which we had not anticipated. Further, a small number of patients underwent PCI more than 48 h after their last fondaparinux administration. Thus, it could be argued that these patients should not have been included in an assessment of physician adherence. However, regardless of whether or not these patients are included in the analysis, because of the very high adjunctive anticoagulant use observed overall during PCI (>90%), this study suggests that for the majority of ACS patients' physicians are following the prescribing information and treatment guidelines and are not using fondaparinux as the sole anticoagulant during PCI.
In conclusion, the results of this study illustrate that physician adherence to the prescribing information for adjunctive anticoagulation during PCI for ACS patients receiving fondaparinux is high. The results were consistent across six countries and in both UA/NSTEMI and STEMI patients. In addition, the rates of adjunctive UFH use during PCI and administration of the recommended dose of fondaparinux were also high. Lastly, consistent with recommendations, the majority (70.4%) of patients undergoing primary PCI for STEMI did not receive fondaparinux within 24 h prior to or during the procedure.
